BRAF inhibitors in non-small cell lung cancer
V Sforza, G Palumbo, P Cascetta, G Carillio, A Manzo… - Cancers, 2022 - mdpi.com
Simple Summary The identification of BRAF mutations in 1.5–3.5% of NSCLC patients
represents a step forward towards new targeted agents for tackling NSCLC. The positive …
represents a step forward towards new targeted agents for tackling NSCLC. The positive …
Significance of BRAF kinase inhibitors for melanoma treatment: from bench to bedside
T Fujimura, Y Fujisawa, Y Kambayashi, S Aiba - Cancers, 2019 - mdpi.com
According to clinical trials, BRAF kinase inhibitors in combination with MEK kinase inhibitors
are among the most promising chemotherapy regimens for the treatment of advanced BRAF …
are among the most promising chemotherapy regimens for the treatment of advanced BRAF …
[PDF][PDF] CONFLICT OF INTEREST
AV Greig, C Linge, G Terenghi, G Grubauer… - J Invest …, 2003 - academia.edu
BRAF protein kinase is a crucial player in melanoma, as it belongs to the highly oncogenic
RAS/RAF/MEK/ERK signaling pathway (Matallanas et al., 2011), is mutated in about 50% of …
RAS/RAF/MEK/ERK signaling pathway (Matallanas et al., 2011), is mutated in about 50% of …
Discovery of a novel ATP-competitive MEK inhibitor DS03090629 that overcomes resistance conferred by BRAF overexpression in BRAF-mutated melanoma
K Takano, Y Munehira, M Hatanaka, R Murakami… - Molecular Cancer …, 2023 - AACR
Patients with melanoma with activating BRAF mutations (BRAF V600E/K) initially respond to
combination therapy of BRAF and MEK inhibitors. However, their clinical efficacy is limited …
combination therapy of BRAF and MEK inhibitors. However, their clinical efficacy is limited …
The “SWOT” of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?
MH Nissan, DB Solit - Current oncology reports, 2011 - Springer
Activating mutations in the BRAF gene are among the most prevalent kinase mutations in
human cancer. BRAF mutations are most frequent in patients with melanoma where they …
human cancer. BRAF mutations are most frequent in patients with melanoma where they …
Therapeutic targets in melanoma: MAPKinase pathway
FG Haluska, N Ibrahim - Current oncology reports, 2006 - Springer
Recent progress in our understanding of the genetic alterations that occur in the
pathogenesis of melanoma provides exciting opportunities for therapy. The most important …
pathogenesis of melanoma provides exciting opportunities for therapy. The most important …
[HTML][HTML] BRAF inhibitors in clinical oncology
Activating mutations of the BRAF oncogene are present in approximately 5-10% of all
human malignancies and lead to constitutive activation of the mitogen activated protein …
human malignancies and lead to constitutive activation of the mitogen activated protein …
[HTML][HTML] The genesis of Zelboraf: Targeting mutant B-Raf in melanoma
MJ Davis, J Schlessinger - The Journal of cell biology, 2012 - ncbi.nlm.nih.gov
The protein kinase B-Raf is a critical component of the Ras/MAPK signaling pathway. An
oncogenic B-Raf mutation that constitutively activates the kinase was identified in z50% of …
oncogenic B-Raf mutation that constitutively activates the kinase was identified in z50% of …
[HTML][HTML] Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
SJ Heidorn, C Milagre, S Whittaker, A Nourry… - Cell, 2010 - cell.com
We describe a mechanism of tumorigenesis mediated by kinase-dead BRAF in the presence
of oncogenic RAS. We show that drugs that selectively inhibit BRAF drive RAS-dependent …
of oncogenic RAS. We show that drugs that selectively inhibit BRAF drive RAS-dependent …
BRAFV600E: Implications for Carcinogenesis and Molecular Therapy
ER Cantwell-Dorris, JJ O'Leary, OM Sheils - Molecular cancer therapeutics, 2011 - AACR
The mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK)
pathway is frequently mutated in human cancer. This pathway consists of a small GTP …
pathway is frequently mutated in human cancer. This pathway consists of a small GTP …